Lomefloxacin

(RS)- 1-ethyl- 6 ,8 -difluoro- 1 ,4-dihydro -7 -(3- methyl-1- piperazinyl) -4-oxo - 3-quinolinecarboxylic acid

  • 98079-51-7 [( RS)- Lomefloxazcin ]
  • 98079-52-8 [( RS)- Lomefloxazcin · monohydrochloride ]
  • 98079-55-1 [(R) - Lomefloxazcin ]
  • 98079-62-0 [( S)- Lomefloxazcin ]

S01AX17, J01MA07

Colorless needles [( RS)- lomefloxacin ]

Fluoroquinolones

Gyrase inhibitor

  • 351.35 g · mol -1 [( RS)- lomefloxacin ]
  • 387.81 g · mol -1 [( RS)- lomefloxacin · monohydrochloride ]
  • 239 to 240.5 ° C [( RS)- lomefloxacin ]
  • 290-300 ° C ( decomposition) [( RS)- lomefloxacin · Monoydrochlorid ]

Attention

  • 246 mg · kg -1 ( LD50, mouse, iv, ( RS)- lomefloxacin )
  • > 4 g · kg -1 ( LD50, Mouse, oral, ( RS)- lomefloxacin )
  • 3.8 g · kg -1 ( LD50, Rat, oral, ( RS)- lomefloxacin )
  • 253 mg · kg -1 ( LD50, mouse, iv, ( RS)- lomefloxacin · monohydrochloride )
  • 1608 mg · kg -1 ( LD50, Mouse, oral, ( RS)- lomefloxacin · monohydrochloride )
  • 328 mg · kg -1 ( LD50, rat, iv, ( RS)- lomefloxacin · monohydrochloride )
  • 1556 mg · kg -1 ( LD50, Rat, oral, ( RS)- lomefloxacin · monohydrochloride )

Template: Infobox chemical / molecular formula search available

Lomefloxacin is an effective antibacterial drug from the group of fluoroquinolones. It is used to treat bacterial infections in ophthalmology and general medicine.

  • 2.1 Chemical and pharmaceutical information 2.1.1 stereoisomerism
  • 2.1.2 manufacture

Clinical information

Areas of application (indications )

Lomefloxacin is orally for bacterial infections of the respiratory tract, the ear-nose -throat region, skin, soft tissue and bone, urinary tract, such as acute and chronic, complicated and uncomplicated infections such as pyelonephritis ( kidney infection ), cystitis, urethritis and infection after surgical interventions in the genitourinary tract, are used.

In ophthalmology lomefloxacin is in the form of eye drops for bacterial infections of the anterior segment of the eye and ocular adnexa; at Blepharoconjunctivitis, conjunctivitis and blepharitis (inflammation of the eyelid ), applied.

Contraindications ( contraindications)

In a hypersensitivity to lomefloxacin, other quinolones or to any of the pharmaceutical excipients; bacterial keratitis; bacterial endophthalmitis; Sunlight or ultraviolet light exposure; Wearing contact lenses; Children and adolescents under the age of 18 should not be treated with lomefloxacin until completion of the growth phase. There is a risk of the disorder of cartilage formation ( arthropathy ).

Interactions with other drugs

Sucralfate and magnesium - or aluminum - containing antacids (eg magaldrate ) and metal cations from other sources can form chelate complexes with lomefloxacin and affect bioavailability. The taking of these substances should therefore be made at least four hours before or at least two hours after taking the drug. Probenecid may slow the elimination of lomefloxacin with co-administration.

Meals delay while taking the absorption of lomefloxacin, global bioavailability is not significantly affected.

Adverse effects (side effects)

Rarely, transient eye burning immediately after application, hypersensitivity reactions with itching and pain. Prolonged therapy with antibiotics is a risk of secondary fungal infection and favoring the growth of non-susceptible bacteria.

Other Information

Chemical and pharmaceutical information

Is used medicinally the Lomefloxacinmonohydrochlorid.

Stereoisomerism

Lomefloxacin has a stereogenic center, therefore, there are two isomers (R)- lomefloxacin, and enantiomeric (S)- lomefloxacin. The drug Okacin ® ( D) contains the racemate [ 1:1 mixture of (R ) -form and the ( S)-form ] of lomefloxacin · monohydrochloride to favor albeit from fundamental considerations, the use of a better or have fewer side effects active enantiomer would be.

(R)- lomefloxacin (above) and (S)- lomefloxacin (bottom)

Production

The multi-stage synthesis of 2,3,4- trifluoroaniline from Lomefloxacin is described in the literature.

History

Lomefloxacin was patented in 1985 by Hokuriku Pharmaceutical Co. and Novartis Pharma GmbH ( Okacin ®) in the form of eye drops for the treatment of bacterial conjunctivitis; and Pfizer in the oral dosage form ( Maxaquin ®) against urinary tract infections, respiratory tract infections, infections of skin and soft tissues in the trade.

Stereochemistry CAS registry number PubChem Anatomical Therapeutic Chemical Classification System DrugBank Dangerous Substances Directive (67/548/EEC) Active ingredient Pathogenic bacteria Allergy European Journal of Clinical Pharmacology
528743
de